SLC5A2 and hydrops fetalis: Among 12251 participants in the DELIVER and EMPEROR-Preserved trials, SGLT2 inhibitors reduced composite cardiovascular death or first hospitalization for HF (HR 0.80 [95% CI 0.73–0.87]) with consistent reductions in both components: cardiovascular death (HR 0.88 [95% CI 0.77–1.00]) and first hospitalization for HF (HR 0.74 [95% CI 0.67–0.83]).